Bleeding Disorders

Bleeding Disorders

A collection of features and news articles published in ASH Clinical News related to bleeding disorders.

Early Phase Trial Shows PB2452 Immediately Reverses Ticagrelor’s Antiplatelet Activity

The monoclonal antibody fragment PB2452 effectively and immediately reversed the antiplatelet effects of ticagrelor in healthy volunteers, according to results from a phase I...
Alexis Thompson, MD, MPH and Thomas Coates, MD

Are New Treatment Options for Beta Thalassemia Ready for Widespread Use?

Patients with transfusion-dependent beta thalassemia, the most severe form of the disease, require lifelong management with red blood cell (RBC) transfusions, presenting a substantial...
WIB_icon

Higher Dose, Longer Duration of Eltrombopag Improves Likelihood of Response in Refractory Severe Aplastic...

The thrombopoietin receptor agonist eltrombopag was approved by the U.S. Food and Drug Administration for the treatment of adults with refractory severe aplastic anemia...

Demystifying Genetic Testing for Bleeding Disorders

When hemophilia and von Willebrand disease (vWD) were first recognized, doctors didn’t diagnose a patient until he (or, much more infrequently, she) experienced a...
On location

Beta-Thalassemia Gene Therapy Continues to Show Efficacy in Longer-Term Follow-up

Updated results from the phase I/II HGB-204 and HGB-207 trials indicated that several patients with severe, transfusion-dependent beta-thalassemia have remained transfusion-free up to four...

Xarelto Manufacturers Settle Lawsuits Over Bleeding Risks

Johnson & Johnson and Bayer, the manufacturers of rivaroxaban (sold as Xarelto), have agreed to pay $775 million to settle thousands of lawsuits over...

EU Panel Recommends Approving Gene Therapy for Thalassemia

Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Bluebird Bio’s lentiglobin gene-therapy product for patients with transfusion-dependent beta-thalassemia. CHMP is...

New Treatment Approved for Hemophilia A

The U.S. Food and Drug Administration approved turoctocog alfa pegol, an extended half-life factor VIII (FVIII) molecule formerly known as N8-GP, for the treatment...
On location

Alemtuzumab Plus Myeloablative Conditioning Reduces Post-Transplant GVHD Risk

For younger patients with sickle cell disease (SCD) who are eligible for a hematopoietic cell transplantation (HCT), adding alemtuzumab lowered the risk of graft-versus-host...

Congress Passes Bipartisan Sickle Cell Bill

The U.S. Congress recently passed the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018, bipartisan legislation...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.